These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 31001265)

  • 1. Targeting Tumor Vascular CD99 Inhibits Tumor Growth.
    Huijbers EJM; van der Werf IM; Faber LD; Sialino LD; van der Laan P; Holland HA; Cimpean AM; Thijssen VLJL; van Beijnum JR; Griffioen AW
    Front Immunol; 2019; 10():651. PubMed ID: 31001265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD99 triggering induces methuosis of Ewing sarcoma cells through IGF-1R/RAS/Rac1 signaling.
    Manara MC; Terracciano M; Mancarella C; Sciandra M; Guerzoni C; Pasello M; Grilli A; Zini N; Picci P; Colombo MP; Morrione A; Scotlandi K
    Oncotarget; 2016 Nov; 7(48):79925-79942. PubMed ID: 27835596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis.
    Rocchi A; Manara MC; Sciandra M; Zambelli D; Nardi F; Nicoletti G; Garofalo C; Meschini S; Astolfi A; Colombo MP; Lessnick SL; Picci P; Scotlandi K
    J Clin Invest; 2010 Mar; 120(3):668-80. PubMed ID: 20197622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted imaging of Ewing sarcoma in preclinical models using a 64Cu-labeled anti-CD99 antibody.
    O'Neill AF; Dearling JL; Wang Y; Tupper T; Sun Y; Aster JC; Calicchio ML; Perez-Atayde AR; Packard AB; Kung AL
    Clin Cancer Res; 2014 Feb; 20(3):678-87. PubMed ID: 24218512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of human single-chain antibody to the CD99 cell surface determinant specifically recognizing Ewing's sarcoma tumor cells.
    Gellini M; Ascione A; Flego M; Mallano A; Dupuis ML; Zamboni S; Terrinoni M; D'Alessio V; Manara MC; Scotlandi K; Picci P; Cianfriglia M
    Curr Pharm Biotechnol; 2013; 14(4):449-63. PubMed ID: 22335486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Production and characterization of monoclonal antibodies against recombinant extracellular domain of CD99.
    Thangaretnam KP; Paramasivam OR; Ramanathan P; Gopisetty G; Rajkumar T
    Hum Antibodies; 2019; 27(1):69-83. PubMed ID: 30282350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical detection of FLI-1 protein expression: a study of 132 round cell tumors with emphasis on CD99-positive mimics of Ewing's sarcoma/primitive neuroectodermal tumor.
    Folpe AL; Hill CE; Parham DM; O'Shea PA; Weiss SW
    Am J Surg Pathol; 2000 Dec; 24(12):1657-62. PubMed ID: 11117787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted therapies in Ewing's sarcoma.
    Scotlandi K
    Adv Exp Med Biol; 2006; 587():13-22. PubMed ID: 17163152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations.
    Nanni P; Landuzzi L; Manara MC; Righi A; Nicoletti G; Cristalli C; Pasello M; Parra A; Carrabotta M; Ferracin M; Palladini A; Ianzano ML; Giusti V; Ruzzi F; Magnani M; Donati DM; Picci P; Lollini PL; Scotlandi K
    Sci Rep; 2019 Aug; 9(1):12174. PubMed ID: 31434953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary Ewing's sarcoma/primitive neuroectodermal tumor of the kidney: a clinicopathologic and immunohistochemical analysis of 11 cases.
    Jimenez RE; Folpe AL; Lapham RL; Ro JY; O'Shea PA; Weiss SW; Amin MB
    Am J Surg Pathol; 2002 Mar; 26(3):320-7. PubMed ID: 11859203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exosomes from CD99-deprived Ewing sarcoma cells reverse tumor malignancy by inhibiting cell migration and promoting neural differentiation.
    De Feo A; Sciandra M; Ferracin M; Felicetti F; Astolfi A; Pignochino Y; Picci P; Carè A; Scotlandi K
    Cell Death Dis; 2019 Jun; 10(7):471. PubMed ID: 31209202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary vulvar and vaginal extraosseous Ewing's sarcoma/peripheral neuroectodermal tumor: diagnostic confirmation with CD99 immunostaining and reverse transcriptase-polymerase chain reaction.
    Vang R; Taubenberger JK; Mannion CM; Bijwaard K; Malpica A; Ordonez NG; Tavassoli FA; Silver SA
    Int J Gynecol Pathol; 2000 Apr; 19(2):103-9. PubMed ID: 10782405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engagement of CD99 Activates Distinct Programs in Ewing Sarcoma and Macrophages.
    Manara MC; Manferdini C; Cristalli C; Carrabotta M; Santi S; De Feo A; Caldoni G; Pasello M; Landuzzi L; Lollini PL; Salamanna F; Dominici S; Fiori V; Magnani M; Lisignoli G; Scotlandi K
    Cancer Immunol Res; 2024 Feb; 12(2):247-260. PubMed ID: 38051221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD99 polymorphisms significantly influence the probability to develop Ewing sarcoma in earlier age and patient disease progression.
    Martinelli M; Parra A; Scapoli L; De Sanctis P; Chiadini V; Hattinger C; Picci P; Zucchini C; Scotlandi K
    Oncotarget; 2016 Nov; 7(47):77958-77967. PubMed ID: 27792997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of KCMF1 by constitutive high CD99 expression is involved in the migratory ability of Ewing's sarcoma cells.
    Kreppel M; Aryee DN; Schaefer KL; Amann G; Kofler R; Poremba C; Kovar H
    Oncogene; 2006 May; 25(19):2795-800. PubMed ID: 16314831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination against CD99 inhibits atherogenesis in low-density lipoprotein receptor-deficient mice.
    van Wanrooij EJ; de Vos P; Bixel MG; Vestweber D; van Berkel TJ; Kuiper J
    Cardiovasc Res; 2008 Jun; 78(3):590-6. PubMed ID: 18250143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved Antitumor Efficacy of Combined Vaccine Based on the Induced HUVECs and DC-CT26 Against Colorectal Carcinoma.
    Zhang Q; Xie C; Wang D; Yang Y; Liu H; Liu K; Zhao J; Chen X; Zhang X; Yang W; Li X; Tian F; Dong Z; Lu J
    Cells; 2019 May; 8(5):. PubMed ID: 31121964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD99 engagement: an effective therapeutic strategy for Ewing tumors.
    Scotlandi K; Baldini N; Cerisano V; Manara MC; Benini S; Serra M; Lollini PL; Nanni P; Nicoletti G; Bernard G; Bernard A; Picci P
    Cancer Res; 2000 Sep; 60(18):5134-42. PubMed ID: 11016640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Application of the in situ hybridization with EWS dual-color break-apart fluorescence probe and anti-CD99 and anti-FLI-1 antibodies in the diagnosis of Ewing's sarcoma/primitive neuroectodermal tumor].
    Liu BY; Yang Y; DU J; Zhang Y; Wang H; Zheng J
    Beijing Da Xue Xue Bao Yi Xue Ban; 2008 Aug; 40(4):358-62. PubMed ID: 18677380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. siRNA associated with immunonanoparticles directed against cd99 antigen improves gene expression inhibition in vivo in Ewing's sarcoma.
    Ramon AL; Bertrand JR; de Martimprey H; Bernard G; Ponchel G; Malvy C; Vauthier C
    J Mol Recognit; 2013 Jul; 26(7):318-29. PubMed ID: 23657987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.